Drug-Induced Hair Loss: Analysis of the Food and Drug Administration's Adverse Events Reporting System Database

被引:0
|
作者
Hill, Rachel C. [1 ]
Zeldin, Steven D. [1 ]
Lipner, Shari R. [2 ]
机构
[1] Weill Cornell Med Coll, New York, NY USA
[2] Weill Cornell Med, Dept Dermatol, New York, NY 10065 USA
关键词
Alopecia; Hair loss; Immunomodulatory agent; Contraceptives; Tumor necrosis factor inhibitor; HORMONE-RELATED PEPTIDE;
D O I
10.1159/000540104
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction: Drug-induced hair loss is one of several causes of hair loss commonly seen in clinical practice, and it is often a daunting task to determine a potential culprit drug when a patient is taking numerous medications. Our objective was to identify drugs responsible for hair loss, using the Food and Drug Administration's Adverse Events Reporting System (FAERS) database, a compilation of drug-related adverse events (AEs). Methods: Using the FAERS database, we queried all domestic reports with the reaction term "alopecia" listed as an AE in patients >= 18 years old from April 1, 1968, to September 29, 2023. Using descriptive statistics, individual agents were grouped by drug class. Results: We analyzed a total of 39,346 hair loss AE reports related to a single agent. Immunomodulatory agents and monoclonal antibodies represented the highest proportion of AE reports for alopecia, followed by hair loss drugs, contraceptives, and antitumor necrosis factor (anti-TNF) biologics. Conclusion: In sum, we showed that immunomodulatory agents and monoclonal antibodies, hair loss drugs, including minoxidil and finasteride, contraceptives, kinase inhibitors, and anti-TNF drugs are most frequently associated with hair loss AEs in the FAERS database. Because many of these drugs are not prescribed primarily for dermatologic indications, our study provides guidance for dermatologists in identifying common medications associated with alopecia.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 50 条
  • [21] Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database
    Crisafulli, Salvatore
    Cutroneo, Paola Maria
    Verhamme, Katia
    Ferrajolo, Carmen
    Ficarra, Vincenzo
    Sottosanti, Laura
    Di Giovanni, Valentina
    Spina, Edoardo
    Trifiro, Gianluca
    EUROPEAN UROLOGY FOCUS, 2022, 8 (05): : 1424 - 1432
  • [22] Predictors of serious adverse drug events from opioids: Results from the Food and Drug Administration Adverse Events Reporting System
    McDonald, Deborah Dillon
    Srisopa, Pornpan
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2021, 33 (12) : 1207 - 1215
  • [23] Reporting Cosmetic Adverse Events to the US Food and Drug Administration
    Katz, Linda M.
    Valenzuela, Claudia
    Sadrieh, Nakissa K.
    DERMATITIS, 2016, 27 (04) : 236 - 237
  • [24] Dalfampridine Associated Serious Adverse Events: An Analysis of Data from the Food and Drug Administration's Adverse Event Reporting System
    Ahmed, Nehad J.
    Alahmari, Abdullah K.
    Alshehri, Ahmed M.
    Almalki, Ziyad S.
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (06): : 1195 - 1199
  • [25] LEVETIRACETAM-INDUCED RHABDOMYOLYSIS: ANALYSIS OF REPORTS FROM THE FOOD AND DRUG ADMINISTRATION'S ADVERSE EVENT REPORTING SYSTEM DATABASE Reply
    Casanova-Molla, J.
    Valls-Sole, J.
    MUSCLE & NERVE, 2017, 56 (06) : E178 - E178
  • [26] Drug-Induced Gynecomastia: Data Mining and Analysis of the FDA Adverse Event Reporting System Database
    Yang, Xiuli
    Zheng, Xiaochun
    Zhang, Miaomiao
    Huang, Jinlong
    Huang, Ping
    Wang, Jiangfeng
    CLINICAL EPIDEMIOLOGY, 2024, 16 : 617 - 630
  • [27] Analysis of Duloxetine-Related Adverse Events Using the Food and Drug Administration Adverse Event Reporting System
    Zhu, Meng
    Lv, Shengxia
    Zhu, Feiye
    Zhang, Yongsheng
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2025, 45 (02) : 96 - 105
  • [28] Frequency of androgenic cutaneous adverse events associated with levonorgestrel intrauterine devices: An analysis of the Food and Drug Administration Adverse Event Reporting System database
    Cassard, Lydia
    Mitchell, Jameson
    Piliang, Melissa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (03) : 588 - 589
  • [29] Adverse events reported to the US Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel
    Dores, Graca M.
    Jason, Christopher
    Niu, Manette T.
    Perez-Vilar, Silvia
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : 1087 - 1100
  • [30] Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system
    Kamath, Ashwin
    SCIENTIFIC REPORTS, 2025, 15 (01):